logo-loader
viewSeelos Therapeutics

Seelos Therapeutics plans to study SLS-002 in patients at risk of suicide

The New York-based company also said it is amending its agreement with Vyera Pharmaceuticals for the development of SLS-002

Seelos Therapeutics - Seelos Therapeutics Inc of New York plans to study its SLS-002 intranasal ketamine depression drug in patients suffering from suicidality in major depressive disorder
Based on feedback from the FDA, Seelos plans to conduct a Phase II Proof of Concept trial

Seelos Therapeutics Inc (NASDAQ:SEEL) announced Monday it plans to study its SLS-002 intranasal ketamine depression drug in patients suffering from suicidality in major depressive disorder (MDD). 

In a statement, the New York-based clinical-stage biopharmaceutical company also said it is amending its agreement with Vyera Pharmaceuticals for the development of SLS-002. 

Seelos said this amendment now removes the requirement to conduct a Phase III trial and converts the one-time cash payment obligation -- owed to Vyera for the commencement of the Phase III trial -- to a series of cash and stock payments over the next nine months.

READ: Seelos Therapeutics names industry veteran Scott Applebaum as lead strategic regulatory consultant

Based on feedback from its Type C meeting with the Food and Drug Administration, Seelos said it plans to conduct a Phase II Proof of Concept trial in MDD.

“Amending this agreement for the development of SLS-002 allows us to proceed with our plans to conduct a Proof of Concept study to evaluate the safety, tolerability, and efficacy of SLS-002, as well as exploring the validation of the Sheehan Suicidality Tracking Scale in this population,” said CEO Raj Mehra.

“Initiating this study in MDD will allow us to pursue development in targeting a huge unmet clinical need as well as potentially provide for a larger market opportunity than PTSD (post-traumatic stress disorder) which we also plan to pursue.”

Seelos' stock recently traded up 3.4% to $0.95 a share in New York.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Seelos Therapeutics

Price: 1.01 USD

NASDAQ:SEEL
Market: NASDAQ
Market Cap: $45.4 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Seelos Therapeutics rings the Nasdaq opening bell

Seelos Therapeutics Inc (NASDAQ: SEEL) CEO Dr Raj Mehra caught up with Proactive after the clinical-stage biopharmaceutical rung the Nasdaq Stock Market opening bell in Times Square, New York. Dr. Mehra says since listing on the exchange in January, the small company has achieved an...

on 08/12/2019

2 min read